Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(Reuters) – India’s Zydus Lifesciences reported third-quarter profit above analysts’ expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market. The drugmaker’s ...

Zydus Lifesciences Ltd. reported US formulation sales that were ahead of expectations during the December quarter on Wednesday, February 5. Despite this, the stock has declined to the lows of the day.

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the 25th anniversary of its Vashi plant. The facility is crucial for ...

Ahmedabad: Pankaj R. Patel, the Chairman of Zydus Lifesciences Limited, has been conferred with the Padma Bhushan by the Government of India. Expressing his gratitude on being bestowed with one of ...

New Delhi: Chairman of Zydus Lifesciences, Pankaj Patel, on Sunday thanked the Government for bestowing Padma Bhushan upon him, and said he was “extremely grateful for the recognition”.

Ahmedabad (Gujarat) [India], January 26 (ANI): Chairman of Zydus Lifesciences, Pankaj Patel, on Sunday expressed his gratitude upon being bestowed with the Padma Bhushan and thanked the Government of ...

Chairman of Zydus Lifesciences, Pankaj Patel, on Sunday expressed his gratitude upon being bestowed with one of India's highest civilian honours and thanked the Government of India for the ...

Zydus Lifesciences Chairman Pankaj R Patel awarded Padma Bhushan for contributions to healthcare innovation. Patel emphasizes India's role in providing affordable and accessible healthcare for a ...

Bino Pathiparampil, Head of Research, Elara Capital, says companies like Dr Reddy’s, Zydus, Cipla, Sun, can sustain a low-double digit EPS growth over the medium term. Low-double digit is 11%, 12%, 13 ...